Market Place
Sourcing Support
KALA BIO Settles Approximately $10.6 Million Of Debt
05 Jan 2026 //
GLOBENEWSWIRE
KALA BIO Closes $10M Common Stock Offering Under Nasdaq Rules
05 Dec 2025 //
GLOBENEWSWIRE
KALA BIO Launches $10M Common Stock Offering On Nasdaq
04 Dec 2025 //
GLOBENEWSWIRE
KALA BIO Secures $6M Investment From Investor David E. Lazar
01 Dec 2025 //
GLOBENEWSWIRE
Kala Bio Plunges After Scrapping Development of lead Drug
30 Sep 2025 //
REUTERS
Kala Bio to Present at HC Wainwright Global Investment Conference
03 Sep 2025 //
GLOBENEWSWIRE
Kala Bio Names Todd Bazemore President, CEO, and Director
02 Sep 2025 //
GLOBENEWSWIRE
KALA BIO`s Q2 2025 Financial Results and Corporate Update
08 Aug 2025 //
GLOBENEWSWIRE
KALA BIO to present at H.C. Wainwright Ophthalmology Conference
06 Aug 2025 //
GLOBENEWSWIRE
KALA BIO Completes Enrollment for KPI-012 CHASE Trial
09 Jul 2025 //
GLOBENEWSWIRE
KALA BIO to Host Event on KPI-012 for Persistent Corneal
07 Jul 2025 //
GLOBENEWSWIRE
KALA BIO to Present at Jefferies Global Healthcare Conference
29 May 2025 //
GLOBENEWSWIRE
Kala Bio Reports Q1 2025 Financials and Corporate Update
14 May 2025 //
GLOBENEWSWIRE
KALA BIO Reports Q4 and Full Year 2024 Results and Update
31 Mar 2025 //
GLOBENEWSWIRE
KALA BIO to Present at TD Cowen Health Care Conference
26 Feb 2025 //
GLOBENEWSWIRE
KALA BIO Announces Chief Executive Officer Transition
12 Feb 2025 //
GLOBENEWSWIRE
KALA BIO Announces $10,750,000 Private Placement
30 Dec 2024 //
GLOBENEWSWIRE
KALA BIO to Present at Piper Sandler 36th Annual Health Conference
27 Nov 2024 //
GLOBENEWSWIRE
KALA BIO Reports Q3 2024 Financial Results and Corporate Update
12 Nov 2024 //
GLOBENEWSWIRE
KALA BIO To Present At H.C. Wainwright Ophthalmology Conference
08 Aug 2024 //
GLOBENEWSWIRE
KALA BIO Reports Q2 2024 Results And Corporate Update
06 Aug 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.